116 related articles for article (PubMed ID: 37572408)
41. Sociodemographic and clinical characteristics of synthetic cannabinoid users in a large psychiatric emergency department in Turkey.
Yalçın M; Tunalı N; Yıldız H; Oğuz A; Gültekin BK
J Addict Dis; 2018; 37(3-4):259-267. PubMed ID: 31581902
[TBL] [Abstract][Full Text] [Related]
42. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set.
Wolfe CE; Wood DM; Dines A; Whatley BP; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Dargan PI;
Neurotoxicology; 2019 Jul; 73():183-187. PubMed ID: 30974132
[TBL] [Abstract][Full Text] [Related]
43. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
[TBL] [Abstract][Full Text] [Related]
44. A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market.
Brandon AM; Antonides LH; Riley J; Epemolu O; McKeown DA; Read KD; McKenzie C
Molecules; 2021 Mar; 26(5):. PubMed ID: 33807614
[TBL] [Abstract][Full Text] [Related]
45. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides.
Devgun JM; Rasin A; Kim T; Mycyk MB; Bryant SM; Wahl MS; DesLauriers C; Navon L; Moritz ED; Thompson TM; Swoboda HD; Lu J; Aks SE
Clin Toxicol (Phila); 2020 Aug; 58(8):821-828. PubMed ID: 31797705
[No Abstract] [Full Text] [Related]
46. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010.
Hoyte CO; Jacob J; Monte AA; Al-Jumaan M; Bronstein AC; Heard KJ
Ann Emerg Med; 2012 Oct; 60(4):435-8. PubMed ID: 22575211
[TBL] [Abstract][Full Text] [Related]
47. Study on the metabolic process of synthetic cannabinoids 4F-MDMB-BINACA and 4F-MDMB-BICA in human liver microsome and zebrafish model via UHPLC-QE Orbitrap MS.
Li H; Qian Z; Zhao Y; Zheng H
Anal Bioanal Chem; 2022 May; 414(13):3905-3916. PubMed ID: 35389093
[TBL] [Abstract][Full Text] [Related]
48. Detection of synthetic cannabinoid adulteration in the unregulated drug supply in three Canadian settings.
Ti L; Tobias S; Maghsoudi N; Milloy MJ; McDonald K; Shapiro A; Beriault D; Stefan C; Lysyshyn M; Werb D
Drug Alcohol Rev; 2021 May; 40(4):580-585. PubMed ID: 33354869
[TBL] [Abstract][Full Text] [Related]
49. Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption.
Kovács K; Kereszty É; Berkecz R; Tiszlavicz L; Sija É; Körmöczi T; Jenei N; Révész-Schmehl H; Institóris L
J Forensic Leg Med; 2019 Jul; 65():92-100. PubMed ID: 31128567
[TBL] [Abstract][Full Text] [Related]
50. Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations.
Bahouth MN; Kraus P; Dane K; Plazas Montana M; Tsao W; Tabaac B; Jasem J; Schmidlin H; Einstein E; Streiff MB; Shanbhag S
Medicine (Baltimore); 2019 Sep; 98(36):e17015. PubMed ID: 31490385
[TBL] [Abstract][Full Text] [Related]
51. Severe neurological symptoms following synthetic cannabinoid intoxication.
van Gorp F; Wejden LC; Stienstra NA; Kuck EM; Haas LEM
Neth J Med; 2017 May; 75(4):158-160. PubMed ID: 28522773
[TBL] [Abstract][Full Text] [Related]
52. Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.
Sznitman SR; Pinsky-Talbi L; Salameh M; Moed T; Bentur Y
Int J Drug Policy; 2020 Mar; 77():102711. PubMed ID: 32126489
[TBL] [Abstract][Full Text] [Related]
53. Suspected Synthetic Cannabinomimetic Intoxication: Case Series and Review.
Baum RA; Bailey A; Chan R; Blumenschein K
J Pharm Pract; 2018 Apr; 31(2):238-243. PubMed ID: 28357892
[TBL] [Abstract][Full Text] [Related]
54. Intoxication from the novel synthetic cannabinoids AB-PINACA and ADB-PINACA: A case series and review of the literature.
Armenian P; Darracq M; Gevorkyan J; Clark S; Kaye B; Brandehoff NP
Neuropharmacology; 2018 May; 134(Pt A):82-91. PubMed ID: 29037744
[TBL] [Abstract][Full Text] [Related]
55. Synthetic Cannabinoids: Psychopharmacology, Clinical Aspects, Psychotic Onset.
Martinotti G; Santacroce R; Papanti D; Elgharably Y; Prilutskaya M; Corazza O
CNS Neurol Disord Drug Targets; 2017; 16(5):567-575. PubMed ID: 28412921
[TBL] [Abstract][Full Text] [Related]
56. Synthetic cannabinoid intoxication: a case series and review.
Harris CR; Brown A
J Emerg Med; 2013 Feb; 44(2):360-6. PubMed ID: 22989695
[TBL] [Abstract][Full Text] [Related]
57. The synthetic cannabinoid 5F-MDMB-PICA: A case series.
Kleis J; Germerott T; Halter S; Héroux V; Roehrich J; Schwarz CS; Hess C
Forensic Sci Int; 2020 Sep; 314():110410. PubMed ID: 32683270
[TBL] [Abstract][Full Text] [Related]
58. Increase in Adverse Reactions Associated with Use of Synthetic Cannabinoids - Anchorage, Alaska, 2015-2016.
Springer YP; Gerona R; Scheunemann E; Shafer SL; Lin T; Banister SD; Cooper MP; Castrodale LJ; Levy M; Butler JC; McLaughlin JB
MMWR Morb Mortal Wkly Rep; 2016 Oct; 65(40):1108-1111. PubMed ID: 27736839
[TBL] [Abstract][Full Text] [Related]
59. Psychotic Disorders in Patients Who Use Synthetic Cannabinoids.
Skryabin VY; Vinnikova MA
J Psychiatr Pract; 2019 Nov; 25(6):485-490. PubMed ID: 31821228
[TBL] [Abstract][Full Text] [Related]
60. The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice.
Trexler KR; Vanegas SO; Poklis JL; Kinsey SG
Drug Alcohol Depend; 2020 Sep; 214():108179. PubMed ID: 32688070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
